Experts Dr Martin Hutchings and Dr Loretta Nastoupil discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. Topics include different agents, efficacy, tolerability, dose step up, treatment duration, challenges in generating order sets, patient experience, comparing immunotherapies, and side effect profiles.